The technology revolves around an innovative monoclonal antibody-based conditioning regimen for enhancing the engraftment of hematopoietic stem cells during bone marrow transplants. It features a novel antibody-drug conjugate that targets CD117, a marker on stem cells, to enable effective transplantation without the harmful side effects of traditional conditioning methods.
The technology in focus encompasses a novel suite of synthetic peptide immunogens, collaboratively developed by leading institutions, aimed at evoking a robust immune response against HIV-1. This breakthrough harnesses the latest advancements in immunology to craft immunogens that elicit broadly neutralizing antibodies in humans, a significant stride in HIV-1 therapeutic and preventive strategies.
The technology pertains to a novel polymer nanoparticle platform designed for the creation of individualized cancer vaccines. It utilizes a two-component system that combines patient-specific peptide neoantigens with immunostimulants within self-assembling nanoparticles. This approach ensures the targeted delivery of neoantigens to the immune system, enhancing the immune response against cancer cells while avoiding the systemic activation often seen with conventional adjuvants.
The technology outlined in the document is focused on the discovery of novel biomarkers for Onchocerciasis, a parasitic disease also known as river blindness, which is transmitted by blackfly vectors. The document describes the identification of the first Onchocerca volvulus-encoded molecules that are adult-specific and can be used as markers for macrofilaricidal activity, which is the ability to kill adult worms.
The technology is centered around the Real Time Quaking Induced Conversion (RT-QuIC) assay, which aims to enhance the detection and discrimination of prion diseases in humans and animals. This assay utilizes recombinant prion protein (rPrPSen) to detect prion-seeded fibrillization, offering a highly specific and ultra-sensitive method for detecting multiple prion diseases across various species. A key innovation of the technology is the use of recombinant bank vole prion protein as a broadly reactive substrate. This substrate, when expressed in E.
The technology in focus is a cutting-edge bivalent vaccine that simultaneously offers protection against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the rabies virus. In pre-clinical trials utilizing mouse models, the vaccine has demonstrated significant immunogenicity, prompting a strong immune response, and has effectively reduced the viral yield of MERS-CoV. Its dual-protective nature sets a new precedent for vaccine development, particularly in the context of zoonotic diseases where the potential for interspecies transmission poses a global health risk.
The technology involves modifying HIV-1 envelope mosaic constructs to enhance the efficacy of HIV vaccines. These modifications target specific regions of the envelope protein, aiming to elicit antibodies similar to potent anti-HIV neutralizing antibodies naturally produced during infection. By replacing highly variable patches in the V1, V2, and V3 loops with defined sequences and eliminating immune-dominant epitopes, the modified constructs induce the production of quaternary antibodies.
The technology is a groundbreaking vaccine formulation developed through a meticulous analysis of tick salivary antigens crucial for parasitism. By examining gene expression in tick salivary glands across various life stages and comparing them with ticks feeding on naturally resistant hosts, key antigens were pinpointed. These antigens target molecules that inhibit host homeostatic responses and are predicted to be secreted toxins, making them ideal candidates for inducing immunity against tick parasitism.
This technology presents a novel strain of transgenic mice where the proto-oncogene c-Cbl (Casitas B-lineage lymphoma) has been engineered with loxP (locus of X-over P1) sites, commonly referred to as "floxed." This design enables the conditional knockout of the c-Cbl gene when the mice are crossed with strains that express the Cre recombinase enzyme. Cre recombinase is an enzyme that can specifically target loxP sites, excising the floxed gene only in the presence of Cre, thus allowing tissue-specific or temporal deletion of the target gene.
This innovative technology centers on advanced peptide-based vaccine formulations that aim to significantly boost T cell-mediated immune responses. The core of this invention is the strategic conjugation of modified peptides with polymers attached to immunostimulants, a design poised to enhance the efficacy of vaccines. This approach not only promises to refine the manufacturing process, making it more efficient but also aims to augment the generation of immune responses, potentially leading to superior vaccine performance against various pathogens.